Association of Lupus Anticoagulant status with Disease Course in SARS-CoV-2 (COVID-19) Infection

Abstract

Background: We investigated the importance of lupus anticoagulant (LA) in patients with SARS-CoV-2. Methods: Medical records of 41 SARS-CoV-2 infected patients were reviewed. Patients were classified into two groups according to the frequency of positive LA test results: “LA (−)” and “LA (+) ≥1” (LA positive at least once). Statistical analysis was performed to determine the association between LA presence and change in LA test results and disease course according to both hospital days (HD) and days after diagnosis (DD). Results: The prevalence of LA was 51.2%. Averagely, the first change in LA test result occurred during DD 12-13 and between HD 9-10. The second change occurred on DD 15-16 and HD 13-14. The presence of LA was associated with severe disease ( P = .004) but was not associated with thrombotic complications or mortality. The change of results from negative to positive or vice versa or the frequency of the changes was not associated with disease severity, thrombotic complications, or mortality. Conclusions: LA positivity can be regarded as one of the findings suggesting more serious SARS-CoV-2 infection.

False Prolongation of Activated Partial Thromboplastin Time with Aminoglycoside Antimicrobial Agents: A Case Report

“…LA is determined through a functional assay in the laboratory, which shows that a phospholipid-dependent clotting time is prolonged and the prolongation is corrected by adding excessive phospholipid. Persistent LA is a typically acquired risk factor for thrombosis and its identification is very important [24]. The patient, in this case, had no history of taking antiplatelet or anticoagulant medications, had no bleeding tendency, and with coagulation function tests within normal limits in previous blood draws.…”